What is X4 Pharmaceuticals?
X4 Pharmaceuticals is a clinical-stage biotechnology enterprise dedicated to the discovery and development of novel therapeutics for rare immune-system diseases. The company maintains a distinct competitive advantage through its proprietary expertise in targeting the CXCR4 receptor. By focusing on oral medicine delivery, X4 Pharmaceuticals addresses critical unmet patient needs, positioning itself as a key innovator in the immunology landscape. Its market position is bolstered by a robust intellectual property portfolio and a clear focus on high-value therapeutic indications.
How much funding has X4 Pharmaceuticals raised?
X4 Pharmaceuticals has raised a total of $600.5M across 10 funding rounds:
Private Equity
$735K
Series A
$37.5M
Series B
$27M
Share Placement
$55M
Private Equity
$55M
Other Financing Round
$20M
Other Financing Round
$105M
Multiple Rounds
$300.3M
Private Equity (2015): $735K, investors not publicly disclosed
Series A (2015): $37.5M led by Cormorant Asset Management
Series B (2017): $27M, investors not publicly disclosed
Share Placement (2021): $55M, investors not publicly disclosed
Private Equity (2022): $55M, investors not publicly disclosed
Other Financing Round (2024): $20M with participation from Hercules Capital
Other Financing Round (2024): $105M, investors not publicly disclosed
Private Equity (2025): $60M supported by Nantahala Capital Management, BVF Partners, Kalehua Capital Management, Deep Track Capital, Bain Capital, New Enterprise Associates, Stonepine Capital Management, and Coastland Capital
Private Equity (2025): $85M, investors not publicly disclosed
Stock/Share Issuance (2025): $155.3M, investors not publicly disclosed
Key Investors in X4 Pharmaceuticals
Nantahala Capital Management
A fundamentally-driven alternative investment firm specializing in micro-cap stocks and applying a private equity-style approach to long-term growth.
BVF Partners
A San Francisco-based private investment partnership that focuses on building concentrated, long-term positions in the biotechnology sector.
Bain Capital
A global private investment firm with extensive experience in life sciences, providing flexible capital solutions and strategic operational support.
What's next for X4 Pharmaceuticals?
With the recent influx of capital, X4 Pharmaceuticals is well-positioned to advance its lead candidates through pivotal clinical trials and regulatory milestones. The company's strategic roadmap likely involves scaling its operational capabilities to support late-stage development and potential commercialization efforts. By leveraging its deep scientific expertise and the backing of sophisticated life sciences investors, X4 Pharmaceuticals aims to solidify its leadership in the CXCR4-targeted therapy market, ultimately driving long-term value for stakeholders and improving patient outcomes in underserved therapeutic areas.
See full X4 Pharmaceuticals company page
